Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry
Elizabeth Hecht; Esther Martin; Idlir Liko; Andrew Mahan; Aniruddha Sahasrabuddhe; Nastaran N Tajoddin; Iain D G Campuzano
mAbs ·
DOI: 10.1080/19420862.2026.2699078
First online July 15, 2026; the PubMed issue citation lists December 2026.
Research guide
This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.
Potential research relevance
Useful when deciding which characterization questions justify a native-MS workflow.
Guide basis: Accessible article and abstract. No expert sign-off or citation count is claimed.